FDA accelerated approval covers relapsed/refractory MCL after ≥2 lines including a BTK inhibitor, positioning sonrotoclax as a potential first-in-class BCL-2 option in this setting. Single-arm ...
Researchers at Moffitt Cancer Center are studying DYV800, a topical cream designed to reduce tumor acidity and help the ...
Dr. Susan MacDonald breaks down the TNM staging system (Tumor, Nodes, Metastasis) to help patients understand their clinical ...
Although the oncology community is buzzing with the potential of circulating tumor DNA (ctDNA) to revolutionize breast cancer ...
Led by Dr. Moran Amit, MD Anderson is spearheading a pioneering clinical trial that combines the active ingredient found in so-called "magic mushrooms" with a rigorous psychotherapy framework. This ...
The second recipe, a turmeric latte, includes milk, turmeric, ginger, cinnamon, black pepper and honey. According to the ...
Pancreatic cancer remains one of the most difficult cancers to treat, with many patients facing a high risk of recurrence ...
Sharing survivorship narratives over years functioned as peer-to-peer hope provision for others confronting breast cancer or ...
SEER 1975–2023 analysis demonstrated a long-term mortality inflection from rising rates to sustained declines, with the ...
Learn about superficial spreading melanoma, from the ABCDE diagnostic rules to the latest in immunotherapy, targeted care and surgical options. Superficial spreading ...
Veppanu represents a scientific milestone as the first-ever proteolysis-targeting chimera (PROTAC) to receive FDA approval.
Molecular/genomic profiling is expanding precision selection of systemic therapy and may enable immunotherapy-driven organ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results